https://youtu.be/3ljxxkDagnQ?si=Alu4mhvHZD4UZGRs

Ytl at 1:03:40

Don't simply buy warrant. If ytlp press down by big player to collect more for another week, the one who buy high premium% player will big loss. Especially mother share already almost RM4. Not wise to collect warrant now.

My interest in investing in the Bursa Malaysia stock market was sparked by the impressive results of the i3 competition in 2014 and 2015. The consistent success of OTB, who ranked first for two consecutive years, demonstrated the potential for substantial returns in the stock market, surpassing the returns offered by fixed deposits.

Initially, I decided to venture into stock market investing without following OTB's public posts on specific counters. I believed that buying after others had already invested would not yield significant profits. Unfortunately, this approach resulted in the loss of my entire investment in 2016.

Despite this setback, I still hold a positive view of OTB's stock selections, which are primarily based on technical and fundamental analysis. My own experiences buying certain counters before and after OTB's recommendations have resulted in profitable outcomes. However, it is crucial to manage greed and risk effectively, as not all counters can maintain upward trends for extended periods. The success of an investment depends on the company's fundamentals and the prevailing business cycle.

I appreciate OTB's willingness to share their fundamental analysis insights through public posts, as it provides valuable learning opportunities. While I may not always follow their recommendations, I recognize that investment decisions are ultimately my responsibility, and blaming others for losses incurred due to impulsive and uninformed investments is unproductive.

Same as Ecoworld RTO case.

Pls have a look after 45 mins https://www.youtube.com/live/StiRWkNT2Wc?si=0JsJ3khl8X7Y_DtI

Let see any news from MSCI index after CNY. so far i still happy with price stand at RM4 and PE only 12.
still more room go up if quarter result is good for next few quarter. Worth to hold (since return still better than fix deposit， EPF or maybank 6% dividend) if no other good stock to invest

@ Dragon328
Thanks for your latest analysis.
I buy YTLPOWER because reading your analysis, just before dividend payout.
Today i already 100% gain on mother share and 220% gain on warrant.
Overall i have 62% return (paper gain) for this year.

I will continue hold mother share. Only will let go call warrant 2 weeks before expired date.
Your reseach is much more better compare to investment bank.

Thanks

Yes. cimb report target is RM 50

https://focusmalaysia.my/featured/glove-vs-steel-through-the-crystal-ball-of-uncle-koon/

This share under kyy stock pick.

Stock: [UCREST]: UCREST BHD

 Apr 24, 2021 11:43 PM | Report Abuse 

Qtr outcome is expected to be red

@joyvest, after your previous statement, pls diam diam collect your ucrest or sell your collected share last 2 weeks at high next week, since result so good.

Time to let this Ucrest fly

Thanks

Read quarter report, under business prospect

Above statement if not happen, not point keep posting here, u will loss your credibility

The Boss in briefing.already mention he not buy and sell his share. Also he have 18% share on hand based on rrcent annual report. Most.of the share is in retailer or shark hand.

Not other major share holder. Recently price up, the operator already eat a lots share and be big share holder to control the market price. Good for operator wash out all margin and collateral player, also force the retailer who trap high at 2018 Rm0.58 sold they share on the way down.

Now we wait and see what happen on next week. If Q result is improving, current price is justify.

Vaccine deal if success is extra bonus to move the price to RM 1.3 (PE10) and above based on qty of dose can make. And PE we want given

I buy cheap, so i hold to see the deal done or fail

Good summary from fengpinglangjin, not bias, follow the briefing.
Good for new join to decide buy on investor briefing or buy on others simply talk

If success pilot run,, 3 month will start delivery

Already have 1 company start tech transfer and will start pilot run soon. Based on first and 2nd briefing, this company at China and 600 mil dose.

Last briefing 150 listen, this briefing 1300 people attend

Congrat who still holding ucrest at low price

Let wait and see the this Tuesday night progress update after last Thursday night briefing.
He did mention some Vaccine manufacturer want to use his network distribute vaccine

UCrest Bhd (0005) reach intra-day high of RM0.44 (+25.7%), and it’s now trading at RM0.415 (+18.6%), could it continue to scale new high?
For those who missed the Webinar ... there will be Mandarin Webinar Tue 8pm Do not missed it !

UCrest Bhd（0005）达到了日内高位RM0.44（+ 25.7％），目前交易价为RM0.415（+ 18.6％），股价能否继续创新高呢？
那些错过了上周的网络研讨会的投资者们...我们将再次在星期二晚上8点举行中文的网络研讨会。不要错过了！

Congrat to all believer in Ucrest. Tomorrow have another one Investor Briefing

Hopefully the Boss will do another investor briering after Q result out end Apr to update us latest vaccine MOU progress

When managing director share the info, i feel comfortable to hold. Especially curent ucrest core business also making profit, better than Solution.

On 16th night sharing, more info still not expose on above part 1 and part 2

This is Part II. Part I here.

—————

5) TARGETED FLOW OF VACCINE MASS DEPLOYMENT.

> Gamaleya develops the vaccine formula, then

> UCREST liaises with Asian vaccine contract manufacturers to produce Sputnik V vaccine and sells full amounts to RIDF (take-or-pay basis), then

> RIDF distributes Sputnik V to Russia and other countries

6) TAKE-OR-PAY BASIS - GUARANTEED REVENUE?

The partnership deal signed between UCREST and RDIF is with take-or-pay basis. This means that all amounts manufactured by UCREST (via Asian contract manufacturing) will be fully paid by RDIF, no matter they actually require those amounts of vaccines or not.

This is probably because RDIF foresees potential vaccine shortage, and would rather have excess (instead of shortage) of vaccines.

7) AS OF 14 APRIL 2021, IS THIS DEAL CONFIRMED?
No. However, management stated the definitive agreement will be signed once the detailed arrangements are finalized.

8) ANY COST & RISK INVOLVED?
From UCREST management, there is no capital expense or investment required (Their core strategy is to add value by navigating political complexities to enable mass manufacturing Sputnik V). Risks: Currency exchange risk and production risk (insufficient contract manufacturing capacity that may refrain UCREST from fulfilling the minimum requirement in a timely manner), payment delay(s) by RDIF.

8) WHY UCREST?

According to management,

- UCREST has well-established medical technology operations in China, Taiwan and Singapore.

- They have been actively engaged in various healthcare projects in combating the virus.

- Their existing iMedic adds value to the Sputnik V mass deployment. Management plans to make available to everyone who is going to be vaccinated with Sputnik V to have free access to the iMedic platform to track the symptoms or side effects. These will improve post-vaccination tracking and healthcare monitoring in the future.

9) SUMMARY
MOU seems to indicate that UCREST would have an additional of revenue and earnings, under zero to minimal cost. ❗️However, MOU may or may not materialise. What will be the final outcome? Time will tell.

DISCLAIMER
Information is compiled from publicly available resources. Also, we are merely attempting to connect the dots, not predicting the future. Our understanding could be inaccurate. Valuation of UCREST stock is beyond scope. There is no BUY/SELL recommendation. Investors own their investment decisions and outcomes.

UCREST UPDATE (16 APRIL 2021)

—————

TLDR
UCREST's strong buying interests on 14 April 2021 intrigued us. Below is the sharing of our best attempt to understand the evolving global COVID-19 vaccine situation, how UCREST fits into the big picture, and what's potentially coming for UCREST, based on their recent MOU and additional elaboration on MOU. ❗️Note: MOU may or may not materialise.

—————

DISCLAIMER
Information is compiled from publicly available resources. Also, we are merely attempting to connect the dots, not predicting the future. Our understanding could be inaccurate. Valuation of UCREST stock is beyond scope. There is no BUY/SELL recommendation. Investors own their investment decisions and outcomes.

—————

This is Part I. Part II here.

—————

1) VACCINE SHORTAGE IS AN ISSUE THAT VARIOUS COUNTRIES AIM TO RESOLVE, BEFORE IT HAPPENS.

Until 12 April 2021, only 773 million jabs of COVID-19 vaccines had been administered across the world - just a little more than 2 per cent of the world’s adult population. The world will manufacture 9.5 billion doses by the end of 2021, but it needs more than 14 billion doses as soon as possible to vaccinate the entire adult population. This is almost 3x the number of vaccines the world was producing in the pre-pandemic period for other diseases.

2) FOUR KEY NAMES: RUSSIA, GAMALEYA, SPUTNIK V, RDIF.

- Russia has an institution, called Gamaleya (Gamaleya National Research Institute of Epidemiology and Microbiology).

- Gamaleya develops Sputnik V, a COVID-19 vaccine.

- Sputnik V has an efficacy rate of 91.6%. Can be stored in conventional refrigerators.

- RDIF (Russian Direct Investment Fund) funds Gameleya's Sputnik V development. RDIF is also responsible for the vaccine mass deployment. Approved in 59 countries. Most recent: India approved Sputnik V for emergency use.

3) BOTTLENECKS THEY POTENTIALLY FACE: CONTRACT MANUFACTURING APPROVALS.

Interestingly, to achieve mass development of Sputnik V, RDIF needs to work together with Asian's vaccine contract manufacturers. However, due to vaccine shortage across a rising number of countries, complex vaccine-politics and nation-protectionism situations could surface. This makes securing overseas contract manufacturers of vaccine a challenge.

This means, RDIF requires external support that's not limited by political complexities to mass manufacture Sputnik V vaccine. UCREST is trying to fill exactly this gap.

4) UCREST COMES TO THE RESCUE.

9 April 2021 UCREST announcement: Partnering with RDIF, UCREST navigates political complexities and manages the vaccine contract manufacturers across Asia to achieve Sputnik V mass manufacture.

This effort aims to produce at least 100 million doses (and maybe up to 1 billion doses) in 2021 an similarly in 2022. 2023 - depending on actual situation.

100 million doses/year = 100,000,000 doses/year.

1 billion doses/year = 1,000,000,000 doses/year.

—————

Part II here.

To have latest info, whatsapp this number that share on FB investor briefing for first hand info 0194009336. Ask for whatsapp and telegram group.

So not need guessing here

Russia try to have more vaccine. RDIF looking more partner to do it. Current vaccine in the world is too less to cover 80% of popolation. And only rich, selfish countries can have it.

My view is Ucrest is better than keyasic, keyasic is like a IT support on Ucrest. Major beneficiary is Ucrest.

I park 40% capital in this Ucrest. My 2nd black horse after PA.

The point is during briefing, only max 150 people join. So this 150 people get first hand info directly from Managing Director on the Deal.

All retailer not really know what going on. So they buy and sell and think they earn big. In actual fact, they miss the biggest jackpot

Tantoro,
Sorry, is FB INVESTOR BRIEFING, NOT YOUTUBE.
Mention wrong.

If follow 乐学 youtube, worth 0.3 to 0.45 long run
sputnik V is a suprise, extra bonus if success. And will give very high earnning, start 3 month later and last 2 year mnimum

The MOU is effective deal.

Super Black horse coming. Hold tight your share if u watch the youtube

This counter better than a lots penny stock if based on last 2 Q report

Hold and see end month Q result. Buy when market not coverage this counter. From one person乐学covering until now, i only see price keep going up. Always sell on good news, drop back, then climb up to next level hgh

No 3 gain is more than 1 and 2. He achieve 48% return

http://www.ucrest.net/2021/04/01/key-asic-and-ucrest-collaborate-with-the-shanxi-provincial-government-in-the-transformation-plan/

https://www.nst.com.my/business/2021/04/678777/key-asic-ucrest-collaborate-shanxi-province-healthcare-industry#:~:text=Key%20ASIC%20Bhd%20and%20UCrest,semiconductor%20industry%20in%20Taiyuan%2C%20China.

If this company can have more business from
1. US Sleep Center, current is 50 out of 3000
2. CHINA Non Govt Medical Institute Association roll out, started May 2020, current is 100 out of 20,000
3. International Alliance of Intelligent Health (IAIH) 820 hospitals involve, started Jan 2021
4. Penetrate to more Europe countries
5. Another 3rd Q growing result to attract investor


The share price will up

66% jhm business in car. D&o is 97%. JHM can not so far behind D&O

From 20th June until today, copper price up 48%

Reason of Commodity Supercycle
1. Capital allocation
2. Pandemic budget
3. Unlimited QE
4. Green economy

Green Metal
1.Silver
2. Cobalt
3. Nickel
4. Copper
5. Aluminium
From Affin Hwang Capital

79% PA revenue from annual report is generate from US. USD from Jun 2020 depreciate 5.56 % but aluminum price up 33.4%

Highest 2117, Close at 2113 aluminum price

Aluminum.price just break new high, 2101. And Norsk hydro up 3.31%

https://www.klsescreener.com/v2/announcements/view/3305389

Boss is longterm investor, they sold warrant with high premium and shift to mother share with dividend in future. They will maintain they holding % until IB join board

2 bil market cap which is RM 4 for SCIB end this year. Which mean every 3 month need up RM 0.5, 25% GAIN. if u trust Dato Karim management team, buy and hold. Last year they delivery the promiss hit RM 1 billion cap for Kpower and SCIB.